Shares of Arctis Biotherapeutics (NASDAQ:ARQT) rose 20% in after-hours trading Friday on news that the FDA approved its drug Zolib (also known as roflumilast) to treat seborrheic dermatitis in people 9 years and older.
of FDA has approved this product. This product is a topical foam that does not contain steroids and has an unlimited duration of use. Arctis said Zolib is the first drug with a new mechanism of action approved for this condition in more than 20 years.
Arctis said it plans to launch the product in the U.S. by the end of January. This product is also approved to treat plaque psoriasis.